1 Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A. 1975, 72 (9): 3666-70.
2 Chu WM. Tumor necrosis factor. Cancer Lett, 2013, 328(2): 222-5.
5 Jie H, You M, Liu H. Progress in study on mechanism of multidrug resistance in tumor and reversal strategy. Chinese Archives of Traditional Chinese Medicine, 2013, 31(7): 1686-90.
7 Wang D, Zhang N, Ye Y, et al. Role and mechanisms of microRNA 503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Mol Med Rep, 2014, 10(6): 3268-74.
8 Daflon-Yunes N, Pinto-Silva FE, Vidal RS, et al. Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Mol Cell Biochem, 2013, 383(1-2): 123-35.
9 Liu J, Chen X. Experimental study of TNFα in reversal of multidrug resistance. Chinese Journal of Experimental Surgery, 1999, 3: 256-8.
10 Chen Y, Wang S, Ye J, et al. Reversal of multidrug resistance by transfection of tumor necrosis factor α and MDR1 antisense RNA into multidrug resistant breast cancer cell line. Chinese Journal of Pathophysiology, 2008, 24(6): 1124-28.
11 Brouckaert P, Takahashi N, van Tiel ST, et al. Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. Int J Cancer, 2004, 109(3): 442-8.
13 Leskow FC, Krasnapolski MA, Urtreger AJ. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients. Curr Pharm Biotechnol, 2011, 12(11): 1961-73.
14 Huang M, Jin J, Sun H, et al. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol, 2008, 62(6): 1015-26.
15 Chen B, Jin F, Lu XL, et al. Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC803 cells. Chinese Journal of Cancer, 2004, 23(4): 396-400.
16 Zou YQ, Hu CP. Advances of protein kinase C and its inhibitor in drug resistance of lung cancer. Int J Respir, 2010, 30(10): 615-18.
17 Ren L, Zhou QH, Gou HF. Study of the efficacy and survival time of human recombinant necrosis factor combined with chemotherapy in the treatment of non-small cell lung cancer. West China Medical Journal, 2008, 23(3): 521-5.